Arima Genomics, Inc., a cancer diagnostics company bringing DNA sequence and structure together to advance cancer therapy selection, today announced a distribution partnership with Active Motif ...

Enhanced Genomics’ 3D multi-omics platform harnessed to rapidly identify multiple novel therapeutic targets that were undetectable using conventional genomic approaches Breakthrough demonstrates the ...

Enhanc3D Genomics (‘Enhanced’), an innovator in 3D genomics technology, today announced the launch of a suite of integrated multi-omics solutions to accelerate and improve the precision of drug ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights that will empower researchers and clinicians to improve human health, today ...

The biggest challenge in drug development is that the process is not an even balance of hit or miss – it is overwhelmingly miss, with around 90% of drugs never making it beyond clinical trials. As a ...

Enhanced Genomics ('Enhanced'), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced it has ...

The partnership enables Fox Chase to become the first NCI-designated Comprehensive Cancer Center to implement clinical testing utilizing Arima's 3D-genomics technology in multiple tumor types as part ...

In particular, genome-wide association studies (GWAS) have pinpointed hundreds of genes associated with disease risk, enabling the development of drugs targeting a broad range of highly prevalent ...

PHILADELPHIA, PA & CARLSBAD, CA — Fox Chase Cancer Center and Arima Genomics, Inc. have launched a first-of-its-kind partnership aimed at bringing advanced cancer diagnostics based on the ...

A great deal has changed since April 2003 when the human genome was first sequenced. Now, Enhanced Genomics (Cambridge, UK) has developed a 3D multi-omic profiling technology, GenLink, that combines ...